FIELD: medicine; pharmaceutics.
SUBSTANCE: group of inventions relates to medicine and pharmaceutics. Objects 1 and 3 are embodiments of a method of treating pulmonary hypertension in an individual having pulmonary hypertension, comprising administering to the individual a composition comprising nanoparticles comprising rapamycin and a protein carrier albumin, where the rapamycin dose in the composition is from 1 to 10 mg/m2, where the nanoparticle composition is administered not more often than once a week, where the individual is a person resistant, refractory or recurrent to at least two previous pulmonary hypertension therapies. Object 2 is a method for improving the results of the six-minute walking distance test (6MWD) in an individual suffering from pulmonary hypertension, where the individual is a person resistant, refractory or recurrent to at least two previous pulmonary hypertension therapies.
EFFECT: reduction of pressure in pulmonary vessels (PVR), increase of cardiac output (CO), improvement of 6-minute walking (6MWD) and reduction of functional class according to WHO classification.
22 cl, 22 dwg, 11 tbl, 5 ex
Title | Year | Author | Number |
---|---|---|---|
NANOPARTICLE, CONTAINING RAPAMYCIN AND ALBUMIN AS ANTI-CANCER AGENT | 2008 |
|
RU2483714C2 |
NANOPARTICLE, CONTAINING RAPAMYCIN AND ALBUMIN AS ANTICANCER AGENT | 2013 |
|
RU2678448C2 |
COMBINATION AND METHODS FOR INTRODUCING THERAPEUTIC AGENTS AND COMBINED THERAPY | 2006 |
|
RU2452482C2 |
COMBINATIONS AND METHODS FOR THERAPEUTIC AGENTS INTRODUCTION AND COMBINED THERAPY | 2012 |
|
RU2632103C2 |
COMBINATIONS AND METHODS FOR ADMINISTRATION OF THERAPEUTIC AGENTS AND COMBINATION THERAPY | 2013 |
|
RU2673805C2 |
COMBINED THERAPY WITH COMPOSITIONS OF TAXANE NANOPARTICLES AND HEDGEHOG INHIBITORS | 2010 |
|
RU2561055C2 |
BIOMARKERS | 2005 |
|
RU2429297C2 |
BIOMARKER | 2005 |
|
RU2385944C2 |
METHODS FOR BLADDER CANCER TREATMENT | 2011 |
|
RU2621640C2 |
INHALATION DOSAGE FORM OF RAPAMYCIN FOR TREATING PULMONARY HYPERTENSION | 2015 |
|
RU2732908C2 |
Authors
Dates
2024-11-22—Published
2019-05-21—Filed